Seven new leaders have been appointed to guide Vanderbilt-Ingram Cancer Center's research programs.

Researchers find that ASTX727, a new oral combination therapy, can prolong survival in TP53-mutated MDS.

Vanderbilt researcher P. Brent Ferrell, MD, is leading one of five projects selected by the 2022 Novartis Institutes for BioMedical Research Global Scholars Program.

Oluwole’s patients often call him “Dr. O,” and he is one of the nation’s top CAR T experts. He is an author of a study published in The New England Journal of Medicine in 2017 that showed CAR T is an effective treatment for refractory large B-cell lymphoma.

Vanderbilt is launching a clinical trial that pairs an experimental vaccine with an established immunotherapy for recurrent, human papilloma virus (HPV)-related oropharyngeal cancer of the head and neck.

Multifaceted study connects early amplified oncogene MDM2 with outcomes and therapy responses.

Pediatric oncologists and cardiologists collaborate on reducing cardiotoxic effects of cancer treatment.

The largest genomic analysis ever conducted of small cell lung cancer tumors (SCLC) has identified genetic subtypes and provided insights into the mechanisms of this aggressive and deadly cancer.

A Vanderbilt study found that a molecular signature that predicts aggressive thyroid cancer could help guide treatment approaches for patients.

At the ripe age of 13, Jason Schwartz made a life-changing decision. Amid cancer treatment for Acute Lymphoblastic Leukemia (ALL), Schwartz was handed an incredible gift that would fuel his life’s work.